Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the dosing of the first participant in a global Phase 1/1b clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE